Medicus Pharma Ltd

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company, which engages in investing in novel life sciences and bio-technology companies. It focuses on identifying, acquiring, and advancing relatively de-risked clinical stage assets through clinical development and commercialization. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.

Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) CEO and chairman Raza Bokhari joined Proactive to discuss the company's recent listing on the Nasdaq, a key milestone for the biotechnology firm. Following their initial public offering (IPO) on the Nasdaq, Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) raised $4 million to fund its ongoing Phase 2 proof-of-concept trial for a promising noninvasive treatment for basal cell carcinoma, the most common form of skin cancer.

Medicus Pharma makes debut on Nasdaq raising $4M to advance skin cancer trial - ICYMI

Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 15, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously announced initial public offering in the United States of 970,000 units, at a price of US$4.125 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share.

Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Medicus Pharma (TSX-V:MDCX) announced the pricing of its US initial public offering (IPO), with 970,000 units priced at $4.125 per unit. Each unit will comprise one common share and one warrant, which are exercisable at $4.64 and have a five-year expiry.

Medicus Pharma announces pricing of US IPO

Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the pricing of its initial public offering in the United States of 970,000 units, at a price of US$4.125 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share.

Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

News for Medicus Pharma Ltd Stock (MDCX)